Search PubMed⌕ Search

Biomedical subjects

E Akalin

Publications and source records attributed to E Akalin.

44 records · Page 3Linked to original sources
PubMed1979

[Clinical trial of parenteral trimethoprim-sulfamethoxazole].

The combination of trimethoprim-sulfamethoxazole has been used successfully in various infections. However the use of the combination was limited, due to the lack of a parenteral form of the drug. In this study a parenteral (i.m.) form of trimethoprim-sulfamethoxazole was given to 35 patients with various infections due to susceptible bacteria to the drug. Twenty-four patients had urinary tract infections, and 7 had various infections with gram negative organisms, and 4 had staphylococcal infections. In patients with urinary tract infection the cure rate was 62.5%. Twenty five per cent of the patients had persistent infection after treatment, and 12,5% had superinfection. The overall cure rate was 71,4% in 35 patients. No side effect was observed.

Administration, Oral↗
PubMedDate not supplied

A randomised, multinational study with sequential therapy comparing ciprofloxacin twice daily and ofloxacin once daily.

In a multinational, open, randomised, controlled clinical study, 474 hospitalised patients with moderate or severe infections were treated with sequential regimens of ofloxacin or ciprofloxacin. Ofloxacin 400 mg once daily or ciprofloxacin 200 mg twice daily were given intravenously for at least 3 days followed by oral treatment with ofloxacin 400 mg once daily or ciprofloxacin 500 mg twice daily. Overall cure rates of 86.8% (85.7%) in the ofloxacin group and 89.6 (89.5%) in the ciprofloxacin group were achieved in the intention-to-treat analysis (per protocol analysis). The overall bacteriological response rate (ofloxacin 89.5%, ciprofloxacin 89.0%) was comparable to the clinical cure rate. Both drugs were well tolerated and adverse events were rarely observed. It is concluded that ofloxacin and ciprofloxacin can be used successfully in the treatment of hospitalised patients with aerobic gram-positive and gram-negative infections. Ofloxacin has the advantage of a once-daily regimen, compared to the twice-daily regimen with ciprofloxacin.

Adolescent↗
PubMedDate not supplied

Sulbactam/ampicillin in the treatment of pediatric infections.

Seventy eight pediatric patients (43 males, 35 females) aged 34 days to 17 years were treated with intravenous or intramuscular sulbactam/ampicillin 3 or 4 times daily for skeletal system infection (10 cases), systemic salmonellosis (2 cases), intrathoracic infection (12 cases), and soft tissue or miscellaneous infections (54 cases). The dose used to treat the majority of patients was 200 mg of ampicillin plus 100 mg of sulbactam per kg/day. The duration of treatment ranged from 8 to 23 days. Sulbactam/ampicillin alone was used in 68 patients. Ten patients were treated with an additional antibacterial agent. The overall cure rate was 98.7% for all 78 study patients. One patient with an abscess in the neck was shown to be infected with a strain of Escherichia coli resistant to sulbactam/ampicillin. Only one patient experienced a rash, but it did not necessitate discontinuation of therapy. This study shows that sulbactam/ampicillin is a safe and effective agent in the treatment of various pediatric infections.

Adolescent↗